Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma
- 17 October 2010
- journal article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 103 (3), 635-640
- https://doi.org/10.1007/s11060-010-0435-y
Abstract
Intrathecal application of liposomal cytarabine (Ara-C) (DepoCyte®) has been associated with neurotoxicity when applied as part of a polychemotherapy regimen. Patients with primary central nervous system lymphoma treated with high-dose systemic methotrexate (MTX)- and Ara-C-based polychemotherapy including six cycles of liposomal Ara-C (50 mg intrathecally every 3 weeks) were prospectively monitored for neurotoxic side-effects. Between November 2005 and February 2009, 149 intrathecal applications of liposomal cytarabine (DepoCyte®) were carried out in 33 patients, 7 (21%) of whom developed an incomplete conus medullaris/cauda equina syndrome with incontinence for bladder (6) and bowel function (3) or lumbosacral polyradicular paresis (1), resolving only incompletely over a follow-up period of 9–30 months. In six of these seven patients, lumbosacral magnetic resonance imaging (MRI) was negative for leptomeningeal infiltration or arachnoiditis. Cerebrospinal fluid (CSF) analysis performed in six of these seven patients showed normal cell count in all and increased total protein in four of them. One patient among these seven suffered a seizure without other identifiable causes. Conus/cauda syndrome has to be considered as a serious potential neurotoxic side-effect in patients receiving liposomal Ara-C as part of a multimodal regimen including high-dose systemic MTX and Ara-C.Keywords
This publication has 20 references indexed in Scilit:
- Long-Term Survival with Favorable Cognitive Outcome after Chemotherapy in Primary Central Nervous System LymphomaAnnals of Neurology, 2010
- Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective studyAnti-Cancer Drugs, 2009
- Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphomaCancer, 2009
- Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabineInternational Journal of Nanomedicine, 2008
- Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemiaBlood, 2007
- Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphomaLeukemia & Lymphoma, 2007
- Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS LymphomaJournal of Clinical Oncology, 2006
- Primary CNS LymphomaJournal of Clinical Oncology, 2006
- Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred RadiotherapyJournal of Clinical Oncology, 2003
- Pharmacokinetics of Intralumbar DTC-101 for the Treatment of Leptomeningeal MetastasesArchives of Neurology, 1995